Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients
0
Zitationen
8
Autoren
2020
Jahr
Abstract
Anemia, for which erythropoiesis-stimulating agents (ESAs) and iron supplements (ISs) are used as preventive measures, presents important difficulties for hemodialysis patients. Nevertheless, the number of physicians able to manage such medications appropriately is not keeping pace with the rapid increase of hemodialysis patients. Moreover, the high cost of ESAs imposes heavy burdens on medical insurance systems. An artificial-intelligence-supported anemia control system (AISACS) trained using administration direction data from experienced physicians has been developed by the authors. For the system, appropriate data selection and rectification techniques play important roles. Decision making related to ESAs poses a multi-class classification problem for which a two-step classification technique is introduced. Several validations have demonstrated that AISACS exhibits high performance with correct classification rates of 72-87% and clinically appropriate classification rates of 92-98%.
Ähnliche Arbeiten
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
1996 · 21.989 Zit.
Anemia of Chronic Disease
2005 · 3.694 Zit.
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 · 2.731 Zit.
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 · 2.167 Zit.
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
2006 · 2.088 Zit.